ABSTRACT. In two patients assay of a-1,6-amyloglucosidase activity by incorporation of [14qglucose into glycogen revealed normal activity in leukocytes, erythrocytes, and fibroblasts, whereas no activity was detected in liver and muscle. No activity in any tissue was found when enzyme activity was assayed by following the release of glucose from a phosphorylase limit dextrin. Labeling of glycogen by incubation with crude tissue homogenates according to the protocol used for the [14Cjglucose method
very few studies. These studies have shown that a variable degree of mucosal damage with a decrease of brush border disaccharidase activities frequently accompanies childhood gastroenteritis (I). It has been shown in newborn lambs infected with rotavirus that there persists, for 4 or more days after complete clinical recovery, a state of accelerated cell turnover with functionally immature cells clothing the villi (4) .
The immature intestine of neonatal rat has been shown to have a low DAO content reflected in a low serum DAO activity (6) . These data aid in understanding our own results. The low DAO activity values in the healing phase of gastroenteritis probably reflect the loss of functional enterocytes replaced in the healing phase by "immature" cells. The normal values found in the acute phase of gastroenteritis probably indicate that time is needed for mucosal damage to occur. Our results further show that patients in the healing phase after severe gastroenteritis tend to have lower serum DAO activity values than patients recovering from moderate gastroenteritis. This finding supports the hypothesis that serum DAO activity might be dependent on the total mass of functional enterocytes (6) , since severe gastroenteritis is most probably accompanied by a heavier loss of functional enterocytesethan gastroenteritis of moderate degree. In the rat, serum DAO activity has been shown to accurately quantitate the length of acute intestinal mucosal injury (7) .
The low serum DAO activity values found in healing gastroenteritis are sometimes lower than those found in acute celiac disease (unpublished data). This would logically mean that loss of functional enterocytes can be more important in gastroenteritis than in acute celiac disease. Literature data tend to support this by showing that a complete destruction of the small gut mucosa along all its length can occur in acute gastroenteritis, whereas in celiac disease the mucosal damage is mainly localized to the proximal intestine (9) . Although isolated serum DAO activity measurements are difficult to interpret because of the wide variation in normal values, we believe serial serum DAO activity measurements may be useful in evaluating the severity of small intestinal functional loss in childhood gastroenteritis. Further serial serum DAO activity measurements may turn out to be a most useful tool in the follow-up of childhood enteropathies.
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I. Barnes The glycogen debranching enzyme oligo-a-1,4-glucan: a-1,4-glucan-4-glycosyltransferase (EC 2.4.1.25)/amylo-1,6-glucosidase (EC 3.2.1.33) is present in all tissues and a deficiency of this enzyme can be diagnosed, in most cases, by assay of enzyme activity in any available tissue. It has been known for some years that the enzyme involved in debranching of a phosphorylase limit dextrin has two different activities-a transferase activity, transferring maltotriosyl or maltosyl units, thereby exposing the a-1,6 linkage, and a hydrolytic activity, acting on the glycosidic bond at the branch point (4) . Both activities seem to be located on the same macromolecule (2, 18) and further breakdown of a phosphorylase limit dextrin depends on the sequential activity of the transferase and the hydrolase.
The combined action of the two activities as well as each one separately can be assayed by various methods (1 I, 12) . Many of these methods are either tedious and cumbersome or require special substrates which are not commercially available (12) . As a result of these limitations the assay based on incorporation of labeled glucose into glycogen has been widely used for diagnosis of a-l,6-amyloglucosidase deficiency (type I11 glycogen storage disease). This assay, which had originally been introduced by Hers (9) on the basis of earlier observations by Lamer and Schliselfeld (16) , is based on the slight reversibility of the hydrolytic activity of a-1,6-amyloglucosidase (10) but its exact mechanism is poorly understood. The assay had initially been applied by Hers to muscle and liver biopsies only (9) but was subsequently used for assays on red (22) and white blood cells (2 1,24) and on fibroblasts (14) . With this method the enzyme activity in leukocytes of proven cases of type I11 glycogen storage disease has been reported as normal by Brandt and DeLuca (3) and in two siblings described by us several years ago (7) . In fibroblasts obtained from two patients DiMauro et al. (8) described only slightly reduced activity and low but significant activity was found by Justice et al. (14) in fibroblasts of another patient. Furthermore, the general "unsuitability" of this assay for assay of amyloglucosidase deficiency in fibroblasts has been reported by Brown et al. (6) and by Maire and Mathieu (1 7).
We have recently examined two patients with a-1,6-amyloglucosidase deficiency with apparently normal incorporation of [14C]glucose into glycogen in leukocytes and in cultured fibroblasts and have been able to show that the observed incorporation of [14C]glucose into glycogen was due to the formation of linkages which could be degraded by the action of P-amylase or of phosphorylase and could therefore be presumed to be a-1,4 bonds.
PATIENTS AND METHODS

Patients. A. H.
The patient was a 2-yr-old Arab boy whose parents were first cousins. Physical examination revealed a thin boy with moonface and a protuberant abdomen due to a grossly enlarged liver. Laboratory examinations were unremarkable except for a blood glucose concentration of 1-2 mM/liter on different occasions and serum aspartate aminotransferase activity of 1000 IU/liter (normal up to 50 IU/liter). Blood lactate was 1.1 mM/liter. A fasting glucagon test was flat whereas a postprandial test showed a rise in blood glucose from 2 to 6.2 mM/ liter. An intravenous galactose tolerance test showed a normal rise in blood glucose.
E.A. A 13-month-old Arab boy was admitted for evaluation of hepatomegaly. E. A. was born after a normal pregnancy and delivery. At the age of 7 months he had a generalized seizure which lasted 10 min and 2 months later he had a similar, although milder, seizure. Both seizures occurred at 0400 h.
On examination he was fat, with round cheeks. His weight was 10.300 kg and his height was 75 cm. The abdomen was distended and the liver was firm, smooth, nontender with a span of 18 cm. The tip of the spleen was palpable. Neurologic examination revealed hypotonia with reduced tendon reflexes.
Laboratory examinations revealed a blood glucose of 2.0-2.5 mM/liter on different occasions, cholesterol 5.8 mM/liter, bilirubin 15-30 pmol/liter, aspartate aminotransferase 240-750 IU/ liter, creatine phosphokinase 183 IU/liter, lactate dehydrogenase 470 IU/liter. All other laboratory examinations, including blood lactate and pyruvate, were unremarkable. Fasting and postprandial glucagon tests were flat. ECG showed right ventricular hypertrophy.
Liver biopsy revealed marked swelling of hepatocytes and accumulation of glycogen. Muscle biopsy (left quadriceps) showed differences in fiber diameter with many central nuclei and perinuclear vacuolization. Type I fibers were large and scarce in comparison to type I1 fibers. Stains for glycogen were positive.
Tissues. Primary cultures of skin fibroblasts were obtained by biopsy. Cell sheets were washed twice with PBS and were detached by trypsinization. The cells were centrifuged and washed 3 times with PBS, suspended in 0.05 M MES buffer, and disrupted by sonication with a Kontes Micro Ultrasonic Cell Disruptor (Kontes, Vineland NJ) for three periods of 1 min at maximal output.
Leukocytes and erythrocytes were isolated as previously described (7), suspended in 0.05 M MES buffer, and disrupted by sonication as described for fibroblasts. Enzyme Assays. Activity of a-1,6-amyloglucosidase was assayed: 1) by measuring the incorporation of [14C]glucose into glycogen as described by Nelson and Larner (19) using 0.05 M MES buffer pH 6.5; and 2) by measuring the release of glucose from a PLD as described by Hers (1 I) using 0.05 M MES buffer instead of histidine buffer in the original method. Phosphorylase limit dextrin was prepared according to Hers et al. (I I) and kept lyophilized at -70" C until used.
I4C-labeled glycogen was prepared by using the assay system for assay of a-1,6-amyloglucosidase by incorporation of [I4C] glucose on a larger scale (using 10-20 times the standard amounts of enzyme and substrate) and purifying the labeled glycogen by repeated precipitation with ethanol, as originally described by Hers (9) .
Glycogen labeled in the a-1,4 linkage (used for control experiments) was prepared by incubation of glycogen with UDP-[I4C] glucose under the conditions used for assay of glycogen synthase (1). . .
Acid and neutral a-1,4-glucosidase was assayed at pH 4.5 and 6.5 (8), with maltose, glycogen, or PLD as substrates. Incubations were carried out for 2 h and the released glucose was determined by a hexokinase method using a commercial kit obtained from Boehringer, Mannheim, F. R. G. and a Centrifichem (Union Carbide, Rye, NY) centrifugal analyzer.
Degradation of labeled glycogen. Glycogen labeled by incubation with [14C]glucose or UDP-[14C]glucose (0.5-2 mg) was suspended in 0.05 M acetate buffer, pH 5.0, and incubated with 2 units of @-amylase in a final volume of 0.4 ml for 60 min at 37" C in a shaking water bath. In preliminary experiments the course of the reaction was followed by taking portions of the incubation mixture at intervals of 15 min for assay of maltose [measured as reducing substances by the neocuproine method on a Technicon Autoanalyzer (Technicon Corp., Tanytown, NY)].
The release of labeled glucose was determined by precipitation of the limit dextrin with 2 volumes of 96% ethanol and meas-urement of l4C radioactivity of the supernatant and of the (twice reprecipitated) precipitate. Assay of a-l,6-amyloglucosidase activity of various tissues by incorporation of [U-'4C]glucose into glycogen (I4C method) revealed normal activity in leukocytes, erythrocytes, and fibroblasts, whereas no activity was detectable in liver or muscle biopsies (Table 1) . No activity in any of the tissues examined was found when enzyme activity was assayed by following the release of glucose from PLD (PLD method).
The observed discrepancies between blood cells and fibroblasts on one hand and liver and muscle on the other hand, as well as the discrepancies between results obtained in leukocytes and fibroblasts when using the two methods, prompted a reexamination of the specificity of the I4C method. Labeling of glycogen by incubation of crude tissue homogenates according to the protocol used for the 14C method and subsequent degradation of the outer portion of the polysaccharide molecule with @-amylase showed that 96-100% of the label initially present in glycogen was retained in the P-amylase limit dextrin. Completeness of Pamylolysis was confirmed by chemical assay of the products as well as by a control experiment which showed that almost all the label could be removed by P-amylase when the initial labeling of glycogen had been camed out by incubation with UDP-[I4C] glucose under the conditions used for assay of glycogen synthase ( Table 2) . @-Amylolysis of glycogen labeled by incubation with the patients fibroblasts (Table 3) or leukocytes (Table 4 ) resulted in release of up to 80% of the label, in contrast to the almost complete recovery of the label in the @-amylase limit dextrin when cells from normal controls sewed as enzyme source.
Addition of Tris, which is known to be a specific inhibitor of a-l,6-amylogluco~ida~e activity (20) , inhibited incorporation of [14C]glucose into glycogen with fibroblasts from the two patients and from a normal control to a similar extent (42 and 72%, * Glycogen was labeled by incubation with [U-14C]glucose and a crude tissue homogenate, purified by repeated precipitation with 70% ethanol, and incubated with P-amylase as described in "Patients and Methods".
All glycogen samples were also incubated without'p-amylase (blanks).
The radioactivity found in the supernatant was corrected for these blank values, which ranged from 1-5% of total radioactivity. * Glycogen was labeled by incubation with a fibroblast homogenate with or without the addition of 0.01 M Tris. Other experimental details as in Table 1 and "Patients and Methods". * Phosphorylase a was used for degradation of labeled glycogen. Other experimental details as described in Table 3 .
t Leukocytes obtained from pooled blood of five normal volunteers.
respectively, versus 6 1 %) ( Table 3 ). The distribution of the [l4C] glucose label between the limit dextrin and the supernatant in preparations obtained by incubation of glycogen and fibroblast extracts in the presence of Tris was similar to that obtained without the inhibitor (not shown). The effects of Tris and of changes in pH of the incubation medium on the labeling pattern obtained by incubation of glycogen and [14C]glucose with a leukocyte homogenate as enzyme source is shown in Table 4 . In a11 preparations incorporation was below pH 6 and a plateau was obtained at pH 6.5-7.5. Addition of 0.01 M Tris inhibited incorporation by about two-thirds in patients and in normal controls. Up to 30% of the ['4C]glucose label incorporated by incubation of leukocyte homogenates from normal controls in the presence of Tris could be removed by subsequent incubation with @-amylase (not shown) or phosphorylase a. When leukocytes of the patients served as enzyme source the proportion removed by P-amylase or phosphorylase was even higher than in preparations labeled without added Tris (Table   4) .
A more detailed pH curve performed with fibroblast preparations from the two patients and from a normal control (Fig. 1) did not reveal differences in the effect of pH on ['4C]glucose incorporation.
Although incorporation of glucose into glycogen decreased at acid pH, the possibility was considered that the hydrolytic activity of acid (lysosomal) or neutral a-1,4-glucosidase known to be active in fibroblasts (6) and leukocytes (15) may also be slightly reversible and that an unusually high activity of these enzymes could have resulted in the observed findings. Table 5 shows that a-glucosidase activity assayed with maltase, glycogen, or PLD as substrates was similar in patients and controls. Table 5 also shows that in cells of the controls, but not of the patient, hydrolysis of PLD at pH 6.5 exceeded that of glycogen. DISCUSSION poration in erythrocytes. In several other patients muscle and
We have shown that an enzyme activity present in leukocytes and fibroblasts of two patients with type I11 glycogen storage disease could catalyze incorporation of ['4C]glucose into linkages on glycogen which could be removed by subsequent incubation with @-amylase or phosphorylase. We initially preferred @-amylase since even highly purified phosphorylase might contain traces of a-l,6-amyloglucosidase, but results with both enzymes were similar. Since chemical analysis of the extent of degradation of glycogen by either enzyme ruled out the possibility that degradation had proceeded beyond the outermost branch points and no significant radioactivity was released from glycogen labeled by incubation with enzyme from normal controls, we assume that incorporation of ['4C]glucose by the enzyme present in the patients' cells was into a-1,4 linkages in glycogen.
The question whether only the glucosidase or both glucosidase and transferase was involved in the incorporation of ['4C]glucose has been the subject of controversy. The data presented by Van Hoof and Hers (23) on patients with incomplete a-1,6-amyloglucosidase deficiency (type IIIB) included one patient with lownormal ['4C]glucose incorporation, normal hydrolytic activity on a glucosyl-Schardinger dextrin, and rudimentary or absent transferase activity in muscle and liver but above normal incor- iiver glucosidase activity was also in the low-normal range but ['4C]glucose incorporation was negligible. These findings led Van Hoof and Hers (23) to conclude that incorporation of [I4C] glucose depended on the hydrolytic activity but that this in itself was not suff~cient to allow incorporation. Cohen and his colleagues (2) found that transferase activity was not required for the net incorporation of ['4C]glucose residues into glycogen. On the other hand, Brown et al. (S) , who studied the structure of the product obtained by incubation of glycogen with [14C]glucose and purified amyloglucosidase concluded that both the hydrolytic and the transferase activity were involved in the reaction.
Although our data point to the formation of a-1,4 rather than 1,6 bonds by an enzyme found in leukocyte and fibroblast homogenates of some patients with type I11 glycogen storage disease, no evidence for the existence of an enzyme with properties differing from those of a-1,6-amyloglucosidase (pH, inhibition by Tris) was obtained. The only suggestion that an additional enzyme may be involved came from the experiments on the leukocyte enzyme (from normal controls) in the presence of Tris which showed some incorporation of glucose into bonds which could be hydrolyzed by @-amylase. Since this phenomenon was found only in leukocytes (80% granulocytes) one may speculate that it is related to the very high neutral a-1,Cglucosidase activity found in granulocytes (1 5).
If the observed incorporation of ['4C]glucose is not due to the activity of an additional enzyme, further work will be necessary to determine whether this "altered" enzyme is limited to blood cells and fibroblasts or whether it is present in all cells, but can express itself only in certain tissues. The data of van Hoof and Hers (23) on glucosidase activity and I4C incorporation in liver and muscle of some patients may be taken as support for the latter possibility.
Our results support the conclusion of Brown et al. (6) and Maire and Mathieu (1 7) that normal ['4C]glucose incorporation in fibroblasts does not rule out type I11 glycogen storage disease and suggest that the same conclusion should apply to leukocytes.
